Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome

Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present a case of AML with an IDH2 mutation treated with a regimen of enasidenib and 5-azacitidine, where thyroiditis was noted to be a part of differentiatio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Case Rep Oncol
Main Authors: Annamaraju, Pavan, Gopishetty, Swathi, Goparaju, Naga, Beasey, Matthew, Kota, Vamsi, Guddati, Achuta K.
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2020
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275196/
https://ncbi.nlm.nih.gov/pubmed/32547385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507613
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki